Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
pharmaphorum23h
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...
pharmaphorum23h
Trial finds benefit for GLP-1 agonist in Parkinson’s
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down ... Lixisenatide is an older drug in the same class as Novo Nordisk’s big-selling Ozempic/Wegovy ...
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
US Woman Sheds 75 kg With ‘Miracle’ Ozempic Drug But She Now Faces New Challenges
While the transformation has contributed to Amy’s regained self-esteem, she has also been sharing her experience to help ...
‘Weight-loss drugs seemed good alternative but...’: How Ozempic led to vision blindness disaster - survivor recounts
A US resident lost around 40 kilos using a weight-loss drug but developed vision problems, to be ultimately diagnosed with ...